DarioHealth Corp Dossier
Qualitative Analysis
Business overview
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company specializing in user-centric, multi-chronic condition digital therapeutics. The company's AI-powered platform integrates connected hardware devices with personalized coaching and data analytics to manage conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth has transitioned from its historical direct-to-consumer (B2C) model to a highly scalable business-to-business-to-consumer (B2B2C) model, partnering with self-insured employers, health plans, and pharmaceutical companies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on securing contracts with large self-insured employers, health plans, and benefit administrators to drive high-margin recurring revenue streams.
Expected impact: Aims to replace non-recurring legacy pharmaceutical revenue with predictable, scalable ARR carrying ~80% non-GAAP gross margins.
Integrating clinically validated behavioral and cardiometabolic AI-powered health solutions to personalize member journeys.
Expected impact: Achieved a 40% improvement in member retention, enhancing clinical outcomes and platform engagement.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To build out mental health capabilities, maternal health, and well-being navigation, creating a comprehensive multi-condition digital health platform.
Financial impact: Instantly boosted scale and B2B2C margins, though a single legacy client non-renewal from Twill impacted 2025 reported revenues.
Strategic Partnerships
Targets the $150 billion sleep apnea market by integrating GreenKey's sleep-first approach with Dario's cardiometabolic and behavioral AI solutions.
Terms: Revenue-sharing and joint commercialization targeting payers nationwide.
Delivers Dario's comprehensive cardiometabolic solution, including its GLP-1 support program, to employers.
Terms: Began contributing to recurring revenues in Q1 2025.